JTT-705
- Product Name
- JTT-705
- CAS No.
- 211513-37-0
- Chemical Name
- JTT-705
- Synonyms
- CS-259;JTT-705;RO4607381;Dalcetrapib;JTT705;JTT 705;Unii-3D050liq3h;JTT-705 USP/EP/BP;Dalcetrapib(JTT-705);JTT-705 (Dalcetrapib);EZSolution Dalcetrapib
- CBNumber
- CB5299629
- Molecular Formula
- C23H35NO2S
- Formula Weight
- 389.59
- MOL File
- 211513-37-0.mol
JTT-705 Property
- Melting point:
- 63-63.5 °C
- Boiling point:
- 528.9±33.0 °C(Predicted)
- Density
- 1.06±0.1 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Store in freezer, under -20°C
- solubility
- insoluble in H2O; ≥12.7 mg/mL in DMSO; ≥80.2 mg/mL in EtOH
- form
- solid
- pka
- 13.95±0.70(Predicted)
N-Bromosuccinimide Price
- Product number
- 89450
- Product name
- Dalcetrapib
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $49
- Updated
- 2024/03/01
- Product number
- 89450
- Product name
- Dalcetrapib
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $227
- Updated
- 2024/03/01
- Product number
- 89450
- Product name
- Dalcetrapib
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $403
- Updated
- 2024/03/01
- Product number
- 89450
- Product name
- Dalcetrapib
- Purity
- ≥98%
- Packaging
- 50mg
- Price
- $1065
- Updated
- 2024/03/01
- Product number
- 007488
- Product name
- Dalcetrapib
- Packaging
- 5mg
- Price
- $566
- Updated
- 2021/12/16
JTT-705 Chemical Properties,Usage,Production
Uses
Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Dalcetrapib is a drug undergoing trials for the treatment of cardiovascular disease, dyslipidemia, peripheral arterial disease (PAD).
Definition
ChEBI: 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester is an anilide.
Biological Activity
cholesteryl ester transfer protein (cetp) is a plasma protein that transfers neutral lipids among the lipoproteins. its most important action is the exchange of cholesteryl esters in high-density lipoprotein (hdl) for triglycerides in very low-density lipoprotein. thus, cetp is a potentially atherogenic protein, and its atherogenicity has been supported by many studies. dalcetrapib is a novel inhibitors of cetp.
in vitro
dalcetrapib achieved 50% inhibition of cetp activity in human plasma at a concentration of 6 μm. the mechanism of action was considered to involve the formation of a disulfide bond between the thiol form of dalcetrapib and the cysteine residue at position 13 (cys13) of cetp. [1].
in vivo
dalcetrapib achieved 95% inhibition of cetp activity in male japanese white rabbits at an oral dose of 30 mg/kg. it increased the plasma hdl cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 or 100 mg/kg once a day for 3 days to male japanese white rabbits [1].
target
rhCETP
IC 50
6 μm for cetp inhibition in human plasma
References
[1] shinkai h, maeda k, yamasaki t, okamoto h, uchida i. bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and s-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. j med chem. 2000;43(19):3566-72.
[2] fayad za, mani v, woodward m, kallend d, abt m, burgess t, fuster v, ballantyne cm, stein ea, tardif jc, rudd jh, farkouh me, tawakol a. safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-plaque): a randomised
JTT-705 Preparation Products And Raw materials
Raw materials
Preparation Products
JTT-705 Suppliers
View Lastest Price from JTT-705 manufacturers
- Product
- JTT-705 211513-37-0
- Price
- US $0.00-0.00/KG
- Min. Order
- 5mg
- Purity
- 99%
- Supply Ability
- 2000tons
- Release date
- 2019-12-31
- Product
- JTT-705 211513-37-0
- Price
- US $3.00/KG
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 100kg
- Release date
- 2019-08-07